Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: A case report

S. S. Patel, A. Attard, Pamela Jacobsen, S. Shergill

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

BACKGROUND: Visual hallucinations are commonly seen in various neurological and psychiatric disorders including schizophrenia. Current models of visual processing and studies in diseases including Parkinsons Disease and Lewy Body Dementia propose that Acetylcholine (Ach) plays a pivotal role in our ability to accurately interpret visual stimuli. Depletion of Ach is thought to be associated with visual hallucination generation. AchEI's have been used in the targeted treatment of visual hallucinations in dementia and Parkinson's Disease patients. In Schizophrenia, it is thought that a similar Ach depletion leads to visual hallucinations and may provide a target for drug treatmentCASE PRESENTATION: We present a case of a patient with Schizophrenia presenting with treatment resistant and significantly distressing visual hallucinations. After optimising treatment for schizophrenia we used Rivastigmine, an AchEI, as an adjunct to treat her symptoms successfully.CONCLUSIONS: This case is the first to illustrate this novel use of an AchEI in the targeted treatment of visual hallucinations in a patient with Schizophrenia. Targeted therapy of this kind can be considered in challenging cases although more evidence is required in this field.
Original languageEnglish
Article number68
JournalBMC Psychiatry
Volume10
DOIs
Publication statusPublished - 7 Sep 2010

Fingerprint

Hallucinations
Cholinesterase Inhibitors
Schizophrenia
Acetylcholine
Rivastigmine
Parkinson Disease
Therapeutics
Lewy Body Disease
Aptitude
Nervous System Diseases
Psychiatry
Dementia
Pharmaceutical Preparations

Keywords

  • Adult Antipsychotic Agents/therapeutic use Cholinesterase Inhibitors/*therapeutic use Drug Resistance Female Hallucinations/*drug therapy Humans Phenylcarbamates/*therapeutic use Schizophrenia/*drug therapy *Schizophrenic Psychology Treatment Outcome

Cite this

Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: A case report. / Patel, S. S.; Attard, A.; Jacobsen, Pamela; Shergill, S.

In: BMC Psychiatry, Vol. 10, 68, 07.09.2010.

Research output: Contribution to journalArticle

@article{12489d73d64343fcb7e4a5009a2b509d,
title = "Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: A case report",
abstract = "BACKGROUND: Visual hallucinations are commonly seen in various neurological and psychiatric disorders including schizophrenia. Current models of visual processing and studies in diseases including Parkinsons Disease and Lewy Body Dementia propose that Acetylcholine (Ach) plays a pivotal role in our ability to accurately interpret visual stimuli. Depletion of Ach is thought to be associated with visual hallucination generation. AchEI's have been used in the targeted treatment of visual hallucinations in dementia and Parkinson's Disease patients. In Schizophrenia, it is thought that a similar Ach depletion leads to visual hallucinations and may provide a target for drug treatmentCASE PRESENTATION: We present a case of a patient with Schizophrenia presenting with treatment resistant and significantly distressing visual hallucinations. After optimising treatment for schizophrenia we used Rivastigmine, an AchEI, as an adjunct to treat her symptoms successfully.CONCLUSIONS: This case is the first to illustrate this novel use of an AchEI in the targeted treatment of visual hallucinations in a patient with Schizophrenia. Targeted therapy of this kind can be considered in challenging cases although more evidence is required in this field.",
keywords = "Adult Antipsychotic Agents/therapeutic use Cholinesterase Inhibitors/*therapeutic use Drug Resistance Female Hallucinations/*drug therapy Humans Phenylcarbamates/*therapeutic use Schizophrenia/*drug therapy *Schizophrenic Psychology Treatment Outcome",
author = "Patel, {S. S.} and A. Attard and Pamela Jacobsen and S. Shergill",
note = "Patel, Sachin S Attard, Azizah Jacobsen, Pamela Shergill, Sukhi eng Case Reports England 2010/09/09 06:00 BMC Psychiatry. 2010 Sep 7;10:68. doi: 10.1186/1471-244X-10-68.",
year = "2010",
month = "9",
day = "7",
doi = "10.1186/1471-244X-10-68",
language = "English",
volume = "10",
journal = "BMC Psychiatry",
issn = "1471-244X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: A case report

AU - Patel, S. S.

AU - Attard, A.

AU - Jacobsen, Pamela

AU - Shergill, S.

N1 - Patel, Sachin S Attard, Azizah Jacobsen, Pamela Shergill, Sukhi eng Case Reports England 2010/09/09 06:00 BMC Psychiatry. 2010 Sep 7;10:68. doi: 10.1186/1471-244X-10-68.

PY - 2010/9/7

Y1 - 2010/9/7

N2 - BACKGROUND: Visual hallucinations are commonly seen in various neurological and psychiatric disorders including schizophrenia. Current models of visual processing and studies in diseases including Parkinsons Disease and Lewy Body Dementia propose that Acetylcholine (Ach) plays a pivotal role in our ability to accurately interpret visual stimuli. Depletion of Ach is thought to be associated with visual hallucination generation. AchEI's have been used in the targeted treatment of visual hallucinations in dementia and Parkinson's Disease patients. In Schizophrenia, it is thought that a similar Ach depletion leads to visual hallucinations and may provide a target for drug treatmentCASE PRESENTATION: We present a case of a patient with Schizophrenia presenting with treatment resistant and significantly distressing visual hallucinations. After optimising treatment for schizophrenia we used Rivastigmine, an AchEI, as an adjunct to treat her symptoms successfully.CONCLUSIONS: This case is the first to illustrate this novel use of an AchEI in the targeted treatment of visual hallucinations in a patient with Schizophrenia. Targeted therapy of this kind can be considered in challenging cases although more evidence is required in this field.

AB - BACKGROUND: Visual hallucinations are commonly seen in various neurological and psychiatric disorders including schizophrenia. Current models of visual processing and studies in diseases including Parkinsons Disease and Lewy Body Dementia propose that Acetylcholine (Ach) plays a pivotal role in our ability to accurately interpret visual stimuli. Depletion of Ach is thought to be associated with visual hallucination generation. AchEI's have been used in the targeted treatment of visual hallucinations in dementia and Parkinson's Disease patients. In Schizophrenia, it is thought that a similar Ach depletion leads to visual hallucinations and may provide a target for drug treatmentCASE PRESENTATION: We present a case of a patient with Schizophrenia presenting with treatment resistant and significantly distressing visual hallucinations. After optimising treatment for schizophrenia we used Rivastigmine, an AchEI, as an adjunct to treat her symptoms successfully.CONCLUSIONS: This case is the first to illustrate this novel use of an AchEI in the targeted treatment of visual hallucinations in a patient with Schizophrenia. Targeted therapy of this kind can be considered in challenging cases although more evidence is required in this field.

KW - Adult Antipsychotic Agents/therapeutic use Cholinesterase Inhibitors/therapeutic use Drug Resistance Female Hallucinations/drug therapy Humans Phenylcarbamates/therapeutic use Schizophrenia/drug therapy Schizophrenic Psychology Treatment Outcome

U2 - 10.1186/1471-244X-10-68

DO - 10.1186/1471-244X-10-68

M3 - Article

VL - 10

JO - BMC Psychiatry

JF - BMC Psychiatry

SN - 1471-244X

M1 - 68

ER -